Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Related News
Insights
Company Spotlight
A clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with diseases of the eye, salivary gland and central nervous system.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
Change in on the way at California’s Vir Biotechnology. 2 August 2024
Pharmaceutical
French pharma major Sanofi revealed it plans to construct a new, state-of-the-art insulin production facility at its BioCampus in Frankfurt Höchst. 2 August 2024
Pharmaceutical
US drugmaker Vertex Pharmaceuticals’ shares closed up 2% at $505.78 yesterday, after it reported consolidated financial results for the second quarter of 2024, and raised its full year product revenue guidance. 2 August 2024
Biotechnology
A change at the top is on the way at Cour Pharmaceuticals, a privately-held US biotech developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases. 1 August 2024
Biotechnology
Japanese drugmaker Otsuka Pharmaceuticals is to buy privately-held US biotech Jnana Therapeutics. 1 August 2024
Pharmaceutical
Eli Lilly released positive top-line results from the SUMMIT Phase III clinical trial evaluating the safety and efficacy of tirzepatide injection in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. 1 August 2024
Biotechnology
French drugmaker Sanofi’s Genzyme subsidiary has launched legal proceedings against US biotech Sarepta Therapeutics. 1 August 2024
Pharmaceutical
Shares in UK pharma major GSK were 2% lower in London’s early afternoon trading on Wednesday. 31 July 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for suzetrigine (VX-548). 31 July 2024
Pharmaceutical
US pharma giant Pfizer has reported its first quarter of sales growth since COVID-19 revenue peaked in late 2022. 30 July 2024
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
29 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze